Bayer Launches Large-scale Pre-launch Trial of New Tomato Varieties with Resistance to Tomato Brown Rugose Fruit Virus (ToBRFV)

Sep 15, 2020 10:10 AM ET
Summary: 
  • The trials, which begin late September in Mexico, will target two varieties of Roma tomatoes which show little or no symptoms of ToBRFV.
  • Developing these varieties aligns with Bayer’s commitment to provide fruit and vegetable seeds from its Seminis and De Ruiter brands which help growers combat the challenges they face each season.

 

Press Release

Monheim, September 15, 2020 /3BL Media/ – Bayer announced today the final large-scale pre-launch trials of Roma-type tomatoes to help growers address Tomato brown rugose fruit virus (ToBRFV). The trials, which begin later this month in Mexico, will include two varieties of Roma-type tomato that claim Intermediate Resistance (IR) to ToBRFV. The type of IR Bayer has seen in these varieties is commonly referred to as the “symptomless carrier,” where, despite the presence of virus particles, the crop can show little or no symptoms of the virus in the leaf and/or fruit should the crop become infected by the virus. Adding ToBRFV in the pathogen list for tomato was discussed during last week’s September meeting of the International Seed Federation.

ToBRFV was first observed in 2014 and spread rapidly to different world areas. This viral disease impacting tomato plants represents a challenge for the industry as it can be transmitted very easily through many vectors including farming tools and equipment, workers’ hands, plants, water, soil, and people.

“ToBRFV can quickly devastate tomato crops, so Bayer worked to develop a product to help growers combat it,” said JD Rossouw, Head of Bayer’s Vegetable Seeds R&D. “Bayer leveraged our global cross-functional teams and extensive research and development pipeline to offer a solution designed to ease the day-to-day challenges faced by growers. Our research continues across several tomato species with the goal of bringing further innovative resistance to growers as quickly as possible.”

Following the trials, Bayer anticipates the products will be available for commercial sale in Mexico in 2021, to later be followed by offerings in other important markets around the world.

The ToBRFV resistance program is part of Bayer’s corporate commitment to Health for All, Hunger for None. It complements the company’s SHIELD program, a comprehensive approach to deliver clean seeds season after season to growers around the world. For more than 10 years, the focus of SHIELD has been on the prevention, detection and elimination of pathogens at our own Bayer production and processing sites, as well as third-party production and processing sites for Seminis and De Ruiter brands.

The SHIELD program continues to incorporate market-leading best practices into seed production and supply. In addition to its strict production protocols that are applicable whatever the growing environment (open field, greenhouse or glasshouse), Bayer has always, and will continue to have, stringent testing measures in place aligned with the International Seed Health Initiative (ISHI) guidelines and any applicable laws, which includes testing our seed for the presence of ToBRFV before it is shipped to customers.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Contact:

Daphne Dorsey, +1-314-406-7627

Email: daphne.dorsey@bayer.com

Find more information at www.bayer.com.
 

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.